Bepirovirsen

About GSK

GSK is a fully focused, global biopharma leader with a market cap exceeding $112B, formed in 2000 and sharpened by the 2022 demerger of its consumer health business. The company leverages deep expertise in vaccines, immunology, and genetics to build a robust pipeline across its four core therapeutic areas. Its strategy is centered on disciplined R&D investment in high-value modalities, including long-acting therapies and next-generation oncology agents, to drive sustainable growth and significant public health impact.

About GSK plc

GSK is a London-headquartered, publicly traded biopharma giant with a market cap of ~$109B, focused exclusively on pharmaceuticals and vaccines following the 2022 spin-off of its consumer health division. Its mission is to positively impact the health of 2.5 billion people by 2030 through disciplined R&D in four core therapeutic areas: Respiratory/Immunology, Oncology, HIV, and Infectious Diseases. The company leverages advanced genetic research, AI, and platform technologies to drive a pipeline of approximately 130 programs, aiming for sustained growth from both its established portfolio and novel pipeline assets.

Therapeutic Areas

Other Chronic Hepatitis B Drugs